Skip to main content
Premium Trial:

Request an Annual Quote

Editas Medicine: Jim Mullen

Jim Mullen has been appointed as CEO of Editas Medicine, where he will replace Cindy Collins. He will take up his new post Feb. 15 and will continue to serve as chairman of the company's board of directors, a role he assumed in March 2018. Previously, Mullen was CEO and a director of Patheon, a contract development and manufacturing organization that was acquired by Thermo Fisher Scientific in 2017. Prior to that, he was president and CEO of Biogen, where he previously held various other positions, including chief operating officer, VP international, and VP of operations. He is also a member of the board of the directors of Thermo Fisher Scientific. Mullen holds a BS in chemical engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.